• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

Briefing Information for the November 5, 2013 Meeting of the Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee (PedsODAC)

 

Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance
-

FDA

Disclaimer: Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. ยง 552).

-
-

Morning Session - Merck Sharp and Dohme Corporation

Disclaimer: The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

-
-

Morning Session - Bristol-Meyers Squibb Company

Disclaimer: The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

-
-

Afternoon Session - Novartis Pharmaceuticals Corporation

Disclaimer: The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

-